trending Market Intelligence /marketintelligence/en/news-insights/trending/cTWMbdzk-bxDw3EOjWimhA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Aevi Genomic Medicine licenses inflammation drug from AstraZeneca's MedImmune

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Aevi Genomic Medicine licenses inflammation drug from AstraZeneca's MedImmune

Aevi Genomic Medicine Inc. has licensed AstraZeneca PLC unit MedImmune Ltd.'s inflammatory disease drug candidate MEDI2338 for further development and commercialization.

Wayne, Pa.-based Aevi Genomic Medicine will pay MedImmune a mid-single-digit million-dollar amount in cash and equity upon exercising the exclusive global license and will pay up to $162 million upon achievement of certain milestones as well as low double-digit royalties on global annual product sales.

Aevi plans to pursue treatment of Still's disease, a rare autoinflammatory disease, with MEDI2338, beginning with a phase 2 trial, according to Aevi's Aug. 7 press release.

Still's disease occurs in adults with elevated levels of interleukin 18 and causes persistent fever, rash and joint pain, as well as liver, cardiopulmonary and kidney complications.

MEDI2338, a monoclonal antibody that targets interleukin 18, could treat other rare autoinflammatory disorders, as interleukin 18 drives inflammation and immunity characteristic of such diseases, Aevi stated.